Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$10.09
Last update: Sep 15, 4:00 PM
Atrium Therapeutics Inc (RNA) Stock Price, Quote, News & History
RNANASDAQ
Atrium Therapeutics (RNA) Stock Price, Quote, News & History | Benzinga
Edge Rankings
Stock Score Locked: Want to See it?
Benzinga Rankings give you vital metrics on any stock – anytime.
Compare
EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
EPS worse than industry
FAQ
How do I buy Atrium Therapeutics (RNA) stock?
You can purchase shares of Atrium Therapeutics (NASDAQ:RNA) through any online brokerage.
Who are Atrium Therapeutics (RNA) competitors?
Other companies in Atrium Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
What is the forecast, or price target, for Atrium Therapeutics (RNA) stock?
Atrium Therapeutics has a consensus price target of $60.10.
What is the current price for Atrium Therapeutics (RNA)?
The stock price for Atrium Therapeutics (NASDAQ: RNA) is $10.09 last updated September 15, 2026 at 4:00 PM EDT.
Does Atrium Therapeutics (RNA) pay a dividend?
There are no upcoming dividends for Atrium Therapeutics.
When is Atrium Therapeutics (NASDAQ:RNA) reporting earnings?
Atrium Therapeutics does not have any upcoming earnings scheduled.
Is Atrium Therapeutics (RNA) going to split?
There is no upcoming split for Atrium Therapeutics.
What sector and industry does Atrium Therapeutics (RNA) operate in?
Atrium Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
